OpGen Stock Forecast, Price & News

OpGen (NASDAQ:OPGN) Frequently Asked Questions

Is OpGen a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OpGen stock.
View analyst ratings for OpGen or view top-rated stocks.

What stocks does MarketBeat like better than OpGen?

Wall Street analysts have given OpGen a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OpGen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting OpGen?

OpGen saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 777,900 shares, an increase of 50.6% from the August 15th total of 516,400 shares. Based on an average daily volume of 1,360,000 shares, the short-interest ratio is presently 0.6 days. Approximately 2.0% of the company's stock are sold short.
View OpGen's Short Interest.

When is OpGen's next earnings date?

OpGen is scheduled to release its next quarterly earnings announcement on Wednesday, November 10th 2021.
View our earnings forecast for OpGen.

How were OpGen's earnings last quarter?

OpGen, Inc. (NASDAQ:OPGN) issued its quarterly earnings results on Thursday, August, 12th. The medical research company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.01. OpGen had a negative net margin of 906.54% and a negative trailing twelve-month return on equity of 99.01%.
View OpGen's earnings history.

How has OpGen's stock been impacted by Coronavirus?

OpGen's stock was trading at $2.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OPGN stock has increased by 47.3% and is now trading at $3.05.
View which stocks have been most impacted by COVID-19.

When did OpGen's stock split? How did OpGen's stock split work?

OpGen's stock reverse split on the morning of Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

What price target have analysts set for OPGN?

2 analysts have issued 1-year target prices for OpGen's stock. Their forecasts range from $4.00 to $7.00. On average, they expect OpGen's share price to reach $5.50 in the next year. This suggests a possible upside of 80.3% from the stock's current price.
View analysts' price targets for OpGen or view top-rated stocks among Wall Street analysts.

Who are OpGen's key executives?

OpGen's management team includes the following people:

• Oliver Schacht, Chief Executive Officer & Director
• Johannes Bacher, Chief Operating Officer
• Vadim Sapiro, Chief Information Officer
• Faranak Atrzadeh, Chief Marketing & Scientific Affairs Officer
• Al Risdorfer, Senior Director-Human Resources

Who are some of OpGen's key competitors?

Some companies that are related to OpGen include Sera Prognostics (SERA), Celcuity (CELC), Exagen (XGN), Centogene (CNTG), Enzo Biochem (ENZ), Viridian Therapeutics (VRDN), Progenity (PROG), Vyant Bio (VYNT), Biocept (BIOC), AnPac Bio-Medical Science (ANPC), Psychemedics (PMD), CannLabs (CANL), PharmChem (PCHM), American Shared Hospital Services (AMS) and American Shared Hospital Services (AMS).
View all of OPGN's competitors.

What other stocks do shareholders of OpGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OpGen investors own include Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Energy Transfer (ET), Vaxart (VXRT), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Pfizer (PFE) and Inovio Pharmaceuticals (INO).

When did OpGen IPO?

(OPGN) raised $17 million in an initial public offering on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager.

What is OpGen's stock symbol?

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

Who are OpGen's major shareholders?

OpGen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.61%), Geode Capital Management LLC (0.84%), State Street Corp (0.26%), Renaissance Technologies LLC (0.23%), Northern Trust Corp (0.19%) and Susquehanna Fundamental Investments LLC (0.13%). Company insiders that own OpGen stock include Evan/ Fa Jones, Johannes Bacher, NV In Liquidation Curetis and Oliver Schacht.
View institutional ownership trends for OpGen.

Which major investors are selling OpGen stock?

OPGN stock was sold by a variety of institutional investors in the last quarter, including National Asset Management Inc., Citadel Advisors LLC, Schonfeld Strategic Advisors LLC, Virtu Financial LLC, and XTX Topco Ltd.
View insider buying and selling activity for OpGen or view top insider-selling stocks.

Which major investors are buying OpGen stock?

OPGN stock was purchased by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, State Street Corp, Vanguard Group Inc., Renaissance Technologies LLC, Susquehanna Fundamental Investments LLC, Millennium Management LLC, Northern Trust Corp, and Charles Schwab Investment Management Inc.. Company insiders that have bought OpGen stock in the last two years include Johannes Bacher, and Oliver Schacht.
View insider buying and selling activity for OpGen or or view top insider-buying stocks.

How do I buy shares of OpGen?

Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OpGen's stock price today?

One share of OPGN stock can currently be purchased for approximately $3.05.

How much money does OpGen make?

OpGen has a market capitalization of $116.72 million and generates $4.21 million in revenue each year. The medical research company earns $-26,210,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis.

How many employees does OpGen have?

OpGen employs 102 workers across the globe.

What is OpGen's official website?

The official website for OpGen is www.opgen.com.

Where are OpGen's headquarters?

OpGen is headquartered at 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878.

How can I contact OpGen?

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at (240) 813-1260 or via email at [email protected].